Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Jason Gerberry
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q3 (8 quarters; questions recorded in 6).
- Questions
- 15on tracked calls
- Challenge rate
- 13%2 of 15 questions
- Companies
- 6questioned at least once
- Reporting periods
- 6with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 15 of 15 questions from 6 companies
VTRSViatris7 questions · 5 reporting periods · 1 of 7 challenging
Calendar 2026 Q2
as I look at the back half of the year, sort of an implied low single-digit growth
Show response
Scott and Paul said China growth continues into 2027 but moderates from 16-17%, all baked into the forecast; direct.
Calendar 2026 Q1
can you discuss your specialty sales force strategy? And what percent of the market are you -- do you think you'll be able to access
Show response
Corinne outlined targeted specialty approach with 150-200 reps focusing on postoperative pain in outpatient settings. Beyond initial targets, partnerships planned to expand reach into nonoperative pain, dentistry, and other segments.
Calendar 2025 Q4
your EBITDA goes up about $150 million or so. It looks like that is largely on the cost restructuring dynamics, but you have +$400 million in revenue
Show response
Doretta cited marginal gross margin decline from mix, LOEs, and lower-margin ARV recovery plus $40M non-recurring TSA income loss. 2026 is a stabilization year with structural expansion becoming visible as savings phase in. Scott corrected that 50% is headcount, NOT COGS efficiency.
Calendar 2025 Q3
just on the enterprise review and just why not an update today versus giving the update on 1Q '26
Show response
Scott explained the delay is about accuracy and credibility, not holding back. Complex project across 165 countries. Wants to deliver numbers that are mapped back to organizations, sustainable, and credible with multi-year phasing.
in a scenario where, I guess, the ban isn't lifted, do the price penalties, which I think were $100 million, did they recur in that scenario
Show response
Doretta confirmed penalties (slightly over 50% of the $100M) will not recur regardless of Indore reinspection outcome. Building redundancies and third-party supply to stabilize revenues independent of import alert.
Calendar 2024 Q4
I know this isn't like a new product issue, but like is generic Symbicort a headwind in 2025, due to competition
Show response
Doretta noted ~20% from already approved products. Corinne confirmed Breyna performing strongly as a key complex generics contributor in 2025.
why does the Indore facility issues have an impact on revenues outside the United States
Show response
Scott explained remediation slows production, causing shortages in some non-US markets despite products being allowed to ship outside US.
BMYBristol Myers Squibb3 questions · 2 reporting periods · 0 of 3 challenging
Calendar 2026 Q2
Just given the really strong launch of JASCAYD by BI, does this impact the bar for success in your view?
Show response
Lenkowsky reframed the competitor launch as market validation, citing a new second-line add-on market and a GI tolerability gap admilparant could fill.
Calendar 2025 Q4
do you see these as agents that maybe you know, appeal more to community providers
Show response
Adam positioned iberdomide as second-line community product with daratumumab combo, offering oral convenience vs bispecifics. Longer-term, CELMoDs to partner with TCEs and cell therapy.
can you remind us why you opted not to enrich in the SSP trial for atherosclerosis
Show response
Cristian explained three stroke event categories (large artery, lacunar, embolic unknown source) are similar between studies, with lacunar events capped. Confident study design is appropriate.
MRKMerck & Co., Inc.2 questions · 2 reporting periods · 1 of 2 challenging
Calendar 2026 Q2
How do you guys think about the opportunity for injectable PCSK9 switch versus the bulk of the opportunity
Show response
Rob Davis said the strategy is market expansion, not share-taking, citing 30 million U.S. patients not at target LDL levels.
Calendar 2026 Q1
does this provide any concerning read-through to some of the ongoing readouts for LITESPARK-022 and the ability to see OS benefit there
Show response
Dean Li expressed strong conviction in the LITESPARK-022 and -011 readouts, cautioning against extrapolating from the 3-agent LITESPARK-012 study to simpler 2-agent combinations.
JNJJohnson & Johnson1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q3
Are there lessons that can be learned that would be useful when ICOTYDE launches an IBD
Show response
Asked by Richard Wagner on for Jason Gerberry. John Reed cited the efficacy, safety and oral-convenience profile plus a combination program in Phase 3.
LLYLilly (Eli)1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q2
I'm wondering if you think these 2 areas, psych and vaccines are areas that Lilly can scale?
Show response
Jake Van Naarden tied the deals to unmet need and disciplined value creation but declined to forward-look on scaling either area.
PFEPfizer1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q4
how you're thinking about the value add of the GLP-one amylin injectable combination relative to the monotherapy
Show response
Boshoff confirmed pursuing both monotherapy and combo approaches for optionality; expects increased efficacy from combination; Malik emphasized early-innings market with diverse patient needs requiring portfolio approach and strong commercial capabilities.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| VTRS Viatris | 7 | 14%1 of 7 questions |
| BMY Bristol Myers Squibb | 3 | 0%none of 3 questions |
| MRK Merck & Co., Inc. | 2 | —Rate withheld: fewer than 3 questions |
| JNJ Johnson & Johnson | 1 | —Rate withheld: fewer than 3 questions |
| LLY Lilly (Eli) | 1 | —Rate withheld: fewer than 3 questions |
| PFE Pfizer | 1 | —Rate withheld: fewer than 3 questions |
- VTRSViatris · 7 questions14%1 of 7 questions
- BMYBristol Myers Squibb · 3 questions0%none of 3 questions
- MRKMerck & Co., Inc. · 2 questions—rate withheld: under 3 questions
- JNJJohnson & Johnson · 1 question—rate withheld: under 3 questions
- LLYLilly (Eli) · 1 question—rate withheld: under 3 questions
- PFEPfizer · 1 question—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 1 |
| 2025 Q1 | No questions recorded | — | — |
| 2025 Q2 | No questions recorded | — | — |
| 2025 Q3 | 2 | 0%none of 2 questions | 1 |
| 2025 Q4 | 4 | 25%1 of 4 questions | 3 |
| 2026 Q1 | 2 | 50%1 of 2 questions | 2 |
| 2026 Q2 | 4 | 0%none of 4 questions | 4 |
| 2026 Q3 | 1 | 0%none of 1 question | 1 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q1No questions recorded
- 2025 Q2No questions recorded
- 2025 Q32 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q44 questions · challenge rate 25% (1 of 4 questions) · 3 companies
- 2026 Q12 questions · challenge rate 50% (1 of 2 questions) · 2 companies
- 2026 Q24 questions · challenge rate 0% (none of 4 questions) · 4 companies
- 2026 Q31 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Competitive Dynamics8
- Product Launch5
- Innovation & R&D3
- Demand2
- Cost Pressure2
- Regulation Policy2
- M&A1
- Capital Allocation1
- Guidance Reliability1
- Geographic Expansion1
Show all 12 topics
- Margin1
- Supply Chain1